United Pharm Total Liabilities
United Pharm total liabilities. Based on the latest financial reports, United Pharm (033270) has total liabilities worth ₩73.64 Billion KRW (≈ $49.91 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check United Pharm liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of United Pharm (2011–2025)
Total liabilities of United Pharm from 2011 to 2025. This chart illustrates how United Pharm's total liabilities have evolved over time, based on quarterly financial data. Explore United Pharm (033270) investment intensity to see how much of total assets are deployed in long-term investments.
United Pharm Competitors by Total Liabilities
The table below lists competitors of United Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shangri La Hotels Malaysia Bhd
KLSE:5517
|
Malaysia | RM354.23 Million |
|
InfuSystems Holdings Inc
NYSE MKT:INFU
|
USA | $39.91 Million |
|
Jochu Technology Co Ltd
TW:3543
|
Taiwan | NT$1.84 Billion |
|
Sun Tekstil Sanayi ve Ticaret A.S.
IS:SUNTK
|
Turkey | TL5.76 Billion |
|
Oriola-KD Oyj B
HE:OKDBV
|
Finland | €830.90 Million |
|
Intermedia Capital Tbk
JK:MDIA
|
Indonesia | Rp3.35 Trillion |
|
A Paradise Acquisition Corp.
NYSE:APAD
|
USA | $8.61 Million |
|
GOCL Corporation Limited
NSE:GOCLCORP
|
India | Rs7.54 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down United Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see United Pharm assets under control.
Liquidity & Leverage Metrics
United Pharm Total Liabilities Ratios Explained
United Pharm total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how United Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for United Pharm (2011–2025)
The table below shows the annual total liabilities of United Pharm from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩64.86 Billion ≈ $43.96 Million |
-4.22% |
| 2024-12-31 | ₩67.72 Billion ≈ $45.89 Million |
-24.90% |
| 2023-12-31 | ₩90.18 Billion ≈ $61.11 Million |
+12.68% |
| 2022-12-31 | ₩80.03 Billion ≈ $54.24 Million |
+0.90% |
| 2021-12-31 | ₩79.32 Billion ≈ $53.76 Million |
+3.63% |
| 2020-12-31 | ₩76.54 Billion ≈ $51.87 Million |
+0.52% |
| 2019-12-31 | ₩76.14 Billion ≈ $51.60 Million |
+3.64% |
| 2018-12-31 | ₩73.47 Billion ≈ $49.79 Million |
+14.59% |
| 2017-12-31 | ₩64.11 Billion ≈ $43.45 Million |
+12.81% |
| 2016-12-31 | ₩56.83 Billion ≈ $38.52 Million |
+2.84% |
| 2014-12-31 | ₩55.27 Billion ≈ $37.45 Million |
+6.07% |
| 2013-12-31 | ₩52.10 Billion ≈ $35.31 Million |
-3.69% |
| 2012-12-31 | ₩54.10 Billion ≈ $36.66 Million |
-5.16% |
| 2011-12-31 | ₩57.04 Billion ≈ $38.66 Million |
-- |
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more